search
Back to results

Examining the Effectiveness of a Group Cognitive-behavioural Treatment Program for Persistent Genital Arousal Disorder

Primary Purpose

Persistent Genital Arousal Disorder

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Cognitive behavioural therapy
Sponsored by
Queen's University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Persistent Genital Arousal Disorder focused on measuring Persistent Genital Arousal Disorder, intervention

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: at least 18 years of age fluent in English have a physician-based diagnosis of PGAD/GPD reside in Ontario, Canada be comfortable answering questions about their health (mental and physical) and sexuality in online surveys be comfortable discussing their mental and physical health and PGAD/GPD symptoms in group online therapy sessions with video on Exclusion Criteria: under the age of 18 years nonfluent in English lack of physician based diagnosis of PGAD/GPD not comfortable with answering questions about mental, physical, sexual health not comfortable with discussing mental and physical health and PGAD/GPD symptoms in group online therapy sessions with video on mental or physical health conditions that preclude involvement in group therapy

Sites / Locations

  • Sexual Health Research Laboratory, Department of Psychology, Queen's UniversityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Cognitive behavioural therapy

Arm Description

The group therapy program (virtual, synchronous) involves elements based in Cognitive Behavioural Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Dialectical Behaviour Therapy (DBT).

Outcomes

Primary Outcome Measures

Symptom intensity
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Symptom intensity
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Symptom intensity
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Symptom intensity
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Symptom intensity
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Symptom intensity
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Symptom intensity
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Symptom intensity
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Symptom intensity
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Symptom intensity
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Symptom intensity
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Symptom distress
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Symptom distress
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Symptom distress
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Symptom distress
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Symptom distress
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Symptom distress
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Symptom distress
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Symptom distress
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Symptom distress
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Symptom distress
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Symptom distress
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.

Secondary Outcome Measures

Symptom catastrophizing
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Symptom catastrophizing
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Symptom catastrophizing
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Symptom catastrophizing
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Symptom catastrophizing
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Symptom catastrophizing
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Symptom catastrophizing
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Symptom catastrophizing
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Symptom catastrophizing
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Symptom catastrophizing
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Symptom catastrophizing
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Symptom self-efficacy
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Symptom self-efficacy
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Symptom self-efficacy
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Symptom self-efficacy
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Symptom self-efficacy
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Symptom self-efficacy
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Symptom self-efficacy
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Symptom self-efficacy
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Symptom self-efficacy
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Symptom self-efficacy
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Symptom self-efficacy
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Resilience
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Resilience
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Resilience
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Resilience
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Resilience
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Resilience
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Resilience
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Resilience
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Resilience
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Resilience
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Resilience
Brief Resilience Scale. Range is 6-30. Higher scores are better.

Full Information

First Posted
June 13, 2023
Last Updated
June 23, 2023
Sponsor
Queen's University
search

1. Study Identification

Unique Protocol Identification Number
NCT05919784
Brief Title
Examining the Effectiveness of a Group Cognitive-behavioural Treatment Program for Persistent Genital Arousal Disorder
Official Title
Examining the Effectiveness of a Group Cognitive-behavioural Treatment Program for Persistent Genital Arousal Disorder/Genitopelvic Dysesthesia
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 24, 2023 (Actual)
Primary Completion Date
December 2026 (Anticipated)
Study Completion Date
December 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Queen's University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study seeks to provide information regarding the effectiveness of a virtual, synchronous cognitive behavioural therapy (CBT) group program for women with Persistent Genital Arousal Disorder/Genitopelvic Dysesthesia (PGAD/GPD). The program consists of 8 weekly sessions of two hours each, which focus on education and understanding, and learning skills and strategies to manage PGAD/GPD symptoms, and related mental health and lifestyle impacts, as well as structured opportunities for discussion and shared reflection. The group therapy program involves elements based in Cognitive Behavioural Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Dialectical Behaviour Therapy (DBT). Participants in the present study will provide responses to online surveys (before, during, and immediately after treatment, also 3 and 6 months after treatment) regarding their PGAD/GPD symptoms, mental health symptoms, and sexual wellness (sexual pleasure and distress).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Persistent Genital Arousal Disorder
Keywords
Persistent Genital Arousal Disorder, intervention

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cognitive behavioural therapy
Arm Type
Experimental
Arm Description
The group therapy program (virtual, synchronous) involves elements based in Cognitive Behavioural Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Dialectical Behaviour Therapy (DBT).
Intervention Type
Behavioral
Intervention Name(s)
Cognitive behavioural therapy
Intervention Description
The group therapy program (virtual, synchronous) involves elements based in Cognitive Behavioural Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Dialectical Behaviour Therapy (DBT).
Primary Outcome Measure Information:
Title
Symptom intensity
Description
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Time Frame
Baseline
Title
Symptom intensity
Description
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Time Frame
Week 1 of program
Title
Symptom intensity
Description
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Time Frame
Week 2 of program
Title
Symptom intensity
Description
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Time Frame
Week 3 of program
Title
Symptom intensity
Description
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Time Frame
Week 4 of program
Title
Symptom intensity
Description
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Time Frame
Week 5 of program
Title
Symptom intensity
Description
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Time Frame
Week 6 of program
Title
Symptom intensity
Description
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Time Frame
Week 7 of program
Title
Symptom intensity
Description
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Time Frame
Week 8 of program
Title
Symptom intensity
Description
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Time Frame
3 months after the end of the program
Title
Symptom intensity
Description
Symptom intensity on a scale of 0 (no symptoms) to 10 (extremely intense symptoms). Range is 0-10. Higher scores are worse.
Time Frame
6 months after the end of the program
Title
Symptom distress
Description
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Time Frame
Baseline
Title
Symptom distress
Description
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Time Frame
Week 1 of program
Title
Symptom distress
Description
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Time Frame
Week 2 of program
Title
Symptom distress
Description
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Time Frame
Week 3 of program
Title
Symptom distress
Description
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Time Frame
Week 4 of program
Title
Symptom distress
Description
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Time Frame
Week 5 of program
Title
Symptom distress
Description
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Time Frame
Week 6 of program
Title
Symptom distress
Description
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Time Frame
Week 7 of program
Title
Symptom distress
Description
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Time Frame
Week 8 of program
Title
Symptom distress
Description
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Time Frame
3 months after the end of the program
Title
Symptom distress
Description
Symptom distress on a scale of 0 (no distress) to 10 (extreme distress). Range is 0-10. Higher scores are worse.
Time Frame
6 months after the end of the program
Secondary Outcome Measure Information:
Title
Symptom catastrophizing
Description
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Time Frame
Baseline
Title
Symptom catastrophizing
Description
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Time Frame
Week 1 of program
Title
Symptom catastrophizing
Description
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Time Frame
Week 2 of program
Title
Symptom catastrophizing
Description
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Time Frame
Week 3 of program
Title
Symptom catastrophizing
Description
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Time Frame
Week 4 of program
Title
Symptom catastrophizing
Description
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Time Frame
Week 5 of program
Title
Symptom catastrophizing
Description
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Time Frame
Week 6 of program
Title
Symptom catastrophizing
Description
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Time Frame
Week 7 of program
Title
Symptom catastrophizing
Description
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Time Frame
Week 8 of program
Title
Symptom catastrophizing
Description
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Time Frame
3 months after the end of the program
Title
Symptom catastrophizing
Description
Pain Catastrophizing Scale, adapted to symptoms. Range is 0-52. Higher scores are worse.
Time Frame
6 months after the end of the program
Title
Symptom self-efficacy
Description
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Time Frame
Baseline
Title
Symptom self-efficacy
Description
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Time Frame
Week 1 of program
Title
Symptom self-efficacy
Description
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Time Frame
Week 2 of program
Title
Symptom self-efficacy
Description
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Time Frame
Week 3 of program
Title
Symptom self-efficacy
Description
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Time Frame
Week 4 of program
Title
Symptom self-efficacy
Description
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Time Frame
Week 5 of program
Title
Symptom self-efficacy
Description
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Time Frame
Week 6 of program
Title
Symptom self-efficacy
Description
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Time Frame
Week 7 of program
Title
Symptom self-efficacy
Description
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Time Frame
Week 8 of program
Title
Symptom self-efficacy
Description
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Time Frame
3 months after the end of the program
Title
Symptom self-efficacy
Description
Pain Self-Efficacy Scale, adapted to symptoms. Range is 0-60. Higher scores are better.
Time Frame
6 months after the end of the program
Title
Resilience
Description
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Time Frame
Baseline
Title
Resilience
Description
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Time Frame
Week 1 of program
Title
Resilience
Description
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Time Frame
Week 2 of program
Title
Resilience
Description
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Time Frame
Week 3 of program
Title
Resilience
Description
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Time Frame
Week 4 of program
Title
Resilience
Description
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Time Frame
Week 5 of program
Title
Resilience
Description
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Time Frame
Week 6 of program
Title
Resilience
Description
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Time Frame
Week 7 of program
Title
Resilience
Description
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Time Frame
Week 8 of program
Title
Resilience
Description
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Time Frame
3 months after the end of the program
Title
Resilience
Description
Brief Resilience Scale. Range is 6-30. Higher scores are better.
Time Frame
6 months after the end of the program
Other Pre-specified Outcome Measures:
Title
Sexual distress
Description
Sexual distress scale. Range is 0-20. Higher scores are worse.
Time Frame
Baseline
Title
Sexual distress
Description
Sexual distress scale. Range is 0-20. Higher scores are worse.
Time Frame
Week 4 of program
Title
Sexual distress
Description
Sexual distress scale. Range is 0-20. Higher scores are worse.
Time Frame
Week 8 of program
Title
Sexual distress
Description
Sexual distress scale. Range is 0-20. Higher scores are worse.
Time Frame
3 months after the end of the program
Title
Sexual distress
Description
Sexual distress scale. Range is 0-20. Higher scores are worse.
Time Frame
6 months after the end of the program
Title
Anxiety
Description
Generalized Anxiety Scale. Range is 0-21. Higher scores are worse.
Time Frame
Baseline
Title
Anxiety
Description
Generalized Anxiety Scale. Range is 0-21. Higher scores are worse.
Time Frame
Week 4 of program
Title
Anxiety
Description
Generalized Anxiety Scale. Range is 0-21. Higher scores are worse.
Time Frame
Week 8 of program
Title
Anxiety
Description
Generalized Anxiety Scale. Range is 0-21. Higher scores are worse.
Time Frame
3 months after the end of the program
Title
Anxiety
Description
Generalized Anxiety Scale. Range is 0-21. Higher scores are worse.
Time Frame
6 months after the end of the program
Title
Depression
Description
Patient Health Questionnaire-9. Range is 0-27. Higher scores are worse.
Time Frame
Baseline
Title
Depression
Description
Patient Health Questionnaire-9. Range is 0-27. Higher scores are worse.
Time Frame
Week 4 of program
Title
Depression
Description
Patient Health Questionnaire-9. Range is 0-27. Higher scores are worse.
Time Frame
Week 8 of program
Title
Depression
Description
Patient Health Questionnaire-9. Range is 0-27. Higher scores are worse.
Time Frame
3 months after the end of the program
Title
Depression
Description
Patient Health Questionnaire-9. Range is 0-27. Higher scores are worse.
Time Frame
6 months after the end of the program
Title
Symptom-related disability
Description
Pain disability index, adapted for symptoms. Range is 0-70. Higher scores are worse.
Time Frame
Baseline
Title
Symptom-related disability
Description
Pain disability index, adapted for symptoms. Range is 0-70. Higher scores are worse.
Time Frame
Week 4 of program
Title
Symptom-related disability
Description
Pain disability index, adapted for symptoms. Range is 0-70. Higher scores are worse.
Time Frame
Week 8 of program
Title
Symptom-related disability
Description
Pain disability index, adapted for symptoms. Range is 0-70. Higher scores are worse.
Time Frame
3 months after the end of the program
Title
Symptom-related disability
Description
Pain disability index, adapted for symptoms. Range is 0-70. Higher scores are worse.
Time Frame
6 months after the end of the program
Title
Sexual function
Description
Arizona Sexual Experiences Scale, adapted in terms of inclusive language. Range is 5-30. Higher scores are worse.
Time Frame
Baseline
Title
Sexual function
Description
Arizona Sexual Experiences Scale, adapted in terms of inclusive language. Range is 5-30. Higher scores are worse.
Time Frame
Week 4 of program
Title
Sexual function
Description
Arizona Sexual Experiences Scale, adapted in terms of inclusive language. Range is 5-30. Higher scores are worse.
Time Frame
Week 8 of program
Title
Sexual function
Description
Arizona Sexual Experiences Scale, adapted in terms of inclusive language. Range is 5-30. Higher scores are worse.
Time Frame
3 months after the end of the program
Title
Sexual function
Description
Arizona Sexual Experiences Scale, adapted in terms of inclusive language. Range is 5-30. Higher scores are worse.
Time Frame
6 months after the end of the program
Title
Alliance
Description
Working Alliance with Therapist: Session Rating Scale. Four scales rated from 0-10 (range is 0-40), with higher scores indicating a better alliance.
Time Frame
Week 1 of program
Title
Alliance
Description
Working Alliance with Therapist: Session Rating Scale. Four scales rated from 0-10 (range is 0-40), with higher scores indicating a better alliance.
Time Frame
Week 2 of program
Title
Alliance
Description
Working Alliance with Therapist: Session Rating Scale. Four scales rated from 0-10 (range is 0-40), with higher scores indicating a better alliance.
Time Frame
Week 3 of program
Title
Alliance
Description
Working Alliance with Therapist: Session Rating Scale. Four scales rated from 0-10 (range is 0-40), with higher scores indicating a better alliance.
Time Frame
Week 4 of program
Title
Alliance
Description
Working Alliance with Therapist: Session Rating Scale. Four scales rated from 0-10 (range is 0-40), with higher scores indicating a better alliance.
Time Frame
Week 5 of program
Title
Alliance
Description
Working Alliance with Therapist: Session Rating Scale. Four scales rated from 0-10 (range is 0-40), with higher scores indicating a better alliance.
Time Frame
Week 6 of program
Title
Alliance
Description
Working Alliance with Therapist: Session Rating Scale. Four scales rated from 0-10 (range is 0-40), with higher scores indicating a better alliance.
Time Frame
Week 7 of program
Title
Alliance
Description
Working Alliance with Therapist: Session Rating Scale. Four scales rated from 0-10 (range is 0-40), with higher scores indicating a better alliance.
Time Frame
Week 8 of program
Title
Therapy group cohesion
Description
The Group Climate Questionnaire. 12 items total, 3 subscales. Items rated from 0 (not at all) to 7 (extremely). Range for each subscale due to averaging items is 0-7. Higher scores are better.
Time Frame
Week 1 of program
Title
Therapy group cohesion
Description
The Group Climate Questionnaire. 12 items total, 3 subscales. Items rated from 0 (not at all) to 7 (extremely). Range for each subscale due to averaging items is 0-7. Higher scores are better.
Time Frame
Week 2 of program
Title
Therapy group cohesion
Description
The Group Climate Questionnaire. 12 items total, 3 subscales. Items rated from 0 (not at all) to 7 (extremely). Range for each subscale due to averaging items is 0-7. Higher scores are better.
Time Frame
Week 3 of program
Title
Therapy group cohesion
Description
The Group Climate Questionnaire. 12 items total, 3 subscales. Items rated from 0 (not at all) to 7 (extremely). Range for each subscale due to averaging items is 0-7. Higher scores are better.
Time Frame
Week 4 of program
Title
Therapy group cohesion
Description
The Group Climate Questionnaire. 12 items total, 3 subscales. Items rated from 0 (not at all) to 7 (extremely). Range for each subscale due to averaging items is 0-7. Higher scores are better.
Time Frame
Week 5 of program
Title
Therapy group cohesion
Description
The Group Climate Questionnaire. 12 items total, 3 subscales. Items rated from 0 (not at all) to 7 (extremely). Range for each subscale due to averaging items is 0-7. Higher scores are better.
Time Frame
Week 6 of program
Title
Therapy group cohesion
Description
The Group Climate Questionnaire. 12 items total, 3 subscales. Items rated from 0 (not at all) to 7 (extremely). Range for each subscale due to averaging items is 0-7. Higher scores are better.
Time Frame
Week 7 of program
Title
Therapy group cohesion
Description
The Group Climate Questionnaire. 12 items total, 3 subscales. Items rated from 0 (not at all) to 7 (extremely). Range for each subscale due to averaging items is 0-7. Higher scores are better.
Time Frame
Week 8 of program

10. Eligibility

Sex
All
Gender Based
Yes
Gender Eligibility Description
Anyone who self-identifies as a woman is eligible to participate.
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: at least 18 years of age fluent in English have a physician-based diagnosis of PGAD/GPD reside in Ontario, Canada be comfortable answering questions about their health (mental and physical) and sexuality in online surveys be comfortable discussing their mental and physical health and PGAD/GPD symptoms in group online therapy sessions with video on Exclusion Criteria: under the age of 18 years nonfluent in English lack of physician based diagnosis of PGAD/GPD not comfortable with answering questions about mental, physical, sexual health not comfortable with discussing mental and physical health and PGAD/GPD symptoms in group online therapy sessions with video on mental or physical health conditions that preclude involvement in group therapy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Caroline Pukall, PhD
Phone
613 533 3200
Email
caroline.pukall@queensu.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Caroline Pukall, PhD
Organizational Affiliation
Queen's University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sexual Health Research Laboratory, Department of Psychology, Queen's University
City
Kingston
State/Province
Ontario
ZIP/Postal Code
K7L 3N6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Caroline Pukall, PhD
Phone
613 533 3200
Email
caroline.pukall@queensu.ca
First Name & Middle Initial & Last Name & Degree
Shannon Coyle, MA
Phone
613 533 3276
Email
shannon.coyle13@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified data will be available to other researchers after publication of the results.
IPD Sharing Time Frame
De-identified data will be available to other researchers for 2 years after publication of the results.
IPD Sharing Access Criteria
Please email the PI at caroline.pukall@queensu.ca

Learn more about this trial

Examining the Effectiveness of a Group Cognitive-behavioural Treatment Program for Persistent Genital Arousal Disorder

We'll reach out to this number within 24 hrs